About the Journal
Aims and Scope
Journal of Immunotherapy and Precision Oncology (JIPO) is a peer-reviewed, open-access journal that is published quarterly by Allen Press (Lawrence, KS, USA). The Journal is owned by the Innovative Healthcare Institute (innovativehci.com).
JIPO aims to publish high-quality manuscripts related to the field of immunotherapy and precision oncology. The content will appeal to a broad readership of healthcare professionals and scientists, especially those with an interest in oncology and immunology. The scope of the Journal includes innovative original research articles related to translational science and clinical medicine, review articles, editorials, case reports, letters, guidelines, and more.
Manuscripts related to clinical and translational discoveries related with immunity and cancer and immunotherapy, such as new discoveries about immune system function and biology, new therapeutic approaches to different malignancies, mechanisms of resistance, clinical assessment, and more will be considered for publication. Subjects related to precision oncology including prognostic or predictive markers and innovative targeted therapy advances in diagnostic technology will also be considered. High quality evidence based guidelines of credible professional entities will also be considered for publication.
Follow Innovations Journals on social media: